To validate our strategy for CTC-enrichment and mutation detection we prospectively obtained peripheral blood samples from 8 patients with metastatic NSCLC harboring EGFR DelEx19 mutations, treated at our center within the LUX-Lung 3 study (EudraCT-No. This evidence concerns the gene EGFR and non-small cell lung carcinoma.